Literature DB >> 4609343

Bioavailability and efficacy of a sustained-release theophylline tablet.

P A Mitenko, R I Ogilvie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4609343     DOI： 10.1002/cpt1974164720

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  10 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

Review 2.  Clinical pharmacokinetics of theophylline.

Authors:  R I Ogilvie
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

3.  The efficacy of Neo-Biphyllin Retard in asthmatic patients--a theophylline slow-releasing coated tablet.

Authors:  H Albrecht; C Messerli; M Scherrer
Journal:  Pneumonologie       Date:  1976-06-25

4.  New method for bioavailability assessment of slow-release preparations of theophylline.

Authors:  Y Kasuya; T Ohno; N Kubota; H Takahashi; H Hirayama
Journal:  J Pharmacokinet Biopharm       Date:  1985-12

5.  Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.

Authors:  Y Horai; T Ishizaki; T Sasaki; K Chiba; T Suganuma; H Echizen; A Ohnishi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet.

Authors:  M Lagas; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  In vitro testing of controlled release theophylline preparations: Theolair, Theograd and Theolin.

Authors:  J P Crombeen; C J De Blaey
Journal:  Pharm Weekbl Sci       Date:  1983-04-29

Review 8.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

9.  Components of variability in serum theophylline concentrations during maintenance therapy with a sustained release formulation.

Authors:  H Halkin; A Mazar; S Almog; Y Schnaps
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Oral sustained-release aminophylline in medical inpatients: factors related to toxicity and plasma theophylline concentrations.

Authors:  L E Ramsay; A Mackay; M L Eppel; J S Oliver
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.